We match the right target with the right modality and execute experiments with rigor to accelerate a steady stream of therapies with transformative or curative potential.
Takeda’s pipeline is dynamic and diverse—most programs are first-in-class molecules that address areas of high unmet need across our core therapeutic areas: Oncology, Rare Genetics & Hematology, Neuroscience and Gastroenterology. We have also established strategic investments in Plasma-Derived Therapies and Vaccines.
Late-stage development programs, key proof-of-concept readouts and lifecycle management milestones
Development pipeline by clinical trial phase